CSOFT joins the Health Sciences industry in recognizing Women’s History Month and the important contributions women make to society. The FDA recently released the 2019 Drug Trials Snapshots Report. This report summarizes the demographic groups represented in the clinical trials for 48 novel drugs approved in 2019. Overall 46,391 patients participated in these trials, of which 72 percent were women.
In celebration of International Women’s Day, CSOFT Health Sciences is bringing together three women leaders who are committed to building a healthier world. By sharing their perspectives, they will impart their wisdom and passion for bringing treatments to patients around the world to improve their life and well-being.
Please follow us for a special upcoming blog post with Amgen VP for JAPAC, CSOFT Health Science Strategic Advisor, Professor Victoria Elegant, CSOFT Health Sciences SVP, Medical Writing & Strategic Partnerships, Dr. Nimita Limaye, and CSOFT International’s CEO Shunee Yee.
CSOFT Health Sciences provides end-to-end medical translations for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in market access consulting and CTD/eCTD submission with the FDA, EMA, and NMPA. Our operation is compliant with ISO 17100 and certified in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more details, please visit www.csoftintl.com.